CL2020000665A1 - Formulaciones tópicas de cloroprocaína y métodos para utilizar las mismas. - Google Patents

Formulaciones tópicas de cloroprocaína y métodos para utilizar las mismas.

Info

Publication number
CL2020000665A1
CL2020000665A1 CL2020000665A CL2020000665A CL2020000665A1 CL 2020000665 A1 CL2020000665 A1 CL 2020000665A1 CL 2020000665 A CL2020000665 A CL 2020000665A CL 2020000665 A CL2020000665 A CL 2020000665A CL 2020000665 A1 CL2020000665 A1 CL 2020000665A1
Authority
CL
Chile
Prior art keywords
chloroprocaine
methods
topical formulations
formulations
doses
Prior art date
Application number
CL2020000665A
Other languages
English (en)
Inventor
Augusto Mitidieri
Elisabetta Donati
Clara Bianchi
Original Assignee
Sintetica S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sintetica S A filed Critical Sintetica S A
Publication of CL2020000665A1 publication Critical patent/CL2020000665A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE PROPORCIONAN DOSIS Y FORMULACIONES TÓPICAS DE CLOROPROCAÍNA, INCLUIDOS GELES Y UNGÜENTOS, Y MÉTODOS DE FABRICACIÓN Y USO DE LAS MISMAS QUE SON EFICACES, QUÍMICAMENTE ESTABLES Y FISIOLÓGICAMENTE BALANCEADAS PARA LA SEGURIDAD Y LA EFICACIA. LAS DOSIS Y FORMULACIONES SON PARTICULARMENTE ÚTILES DURANTE LOS PROCEDIMIENTOS OFTÁLMICOS O EN RESPUESTA A ABRASIONES O TRAUMATISMOS OFTÁLMICOS EN FUNCIÓN DE SU TOLERABILIDAD Y FARMACOCINÉTICA.
CL2020000665A 2017-09-15 2020-03-13 Formulaciones tópicas de cloroprocaína y métodos para utilizar las mismas. CL2020000665A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762559220P 2017-09-15 2017-09-15

Publications (1)

Publication Number Publication Date
CL2020000665A1 true CL2020000665A1 (es) 2020-09-21

Family

ID=63713967

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020000665A CL2020000665A1 (es) 2017-09-15 2020-03-13 Formulaciones tópicas de cloroprocaína y métodos para utilizar las mismas.

Country Status (23)

Country Link
US (3) US10792271B2 (es)
EP (1) EP3681473A1 (es)
JP (1) JP2020533321A (es)
KR (1) KR20200053476A (es)
CN (1) CN111163756B (es)
AU (1) AU2018332212B2 (es)
BR (1) BR112020003095A2 (es)
CA (1) CA3070336C (es)
CL (1) CL2020000665A1 (es)
CO (1) CO2020002985A2 (es)
CR (1) CR20200133A (es)
CU (1) CU20200019A7 (es)
EA (1) EA202090735A1 (es)
EC (1) ECSP20022313A (es)
IL (1) IL273213A (es)
JO (1) JOP20200010A1 (es)
MA (1) MA50241A (es)
MX (1) MX2020002898A (es)
PE (1) PE20201281A1 (es)
PH (1) PH12020550029A1 (es)
SG (1) SG11202000992RA (es)
WO (1) WO2019053657A1 (es)
ZA (1) ZA202000601B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202139993A (zh) * 2020-03-16 2021-11-01 瑞士商辛鐵堤卡公司 具有經改良之功能性的眼用氯普魯卡因(chloroprocaine)凝膠

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218428B1 (en) * 2000-04-28 2001-04-17 Emil Chynn Ophthalmic composition
JP2004123634A (ja) * 2002-10-03 2004-04-22 Lion Corp 眼科用組成物
JP2006513224A (ja) * 2002-12-20 2006-04-20 ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ エステル局所麻酔薬の組み合わせ
US20050137177A1 (en) * 2003-12-18 2005-06-23 Shafer Steven L. Ester combination local anesthetic
CA2596194A1 (en) * 2004-11-24 2006-06-01 Algorx Pharmaceuticals, Inc. Capsaicinoid gel formulation and uses thereof
ITMI20051633A1 (it) 2005-09-06 2007-03-07 Sint Sa Nuovo uso di una composizione comprendente cloroprocaina hcl nuova composizione comprendente cloroprocaina hcl e metodo per la sua fabbricazione
CN103405576B (zh) * 2013-08-23 2016-03-30 何学忠 一种治疗由焊接强光辐射引起的眼部疾病的滴眼液

Also Published As

Publication number Publication date
US20240216323A1 (en) 2024-07-04
CA3070336C (en) 2022-08-23
SG11202000992RA (en) 2020-03-30
MA50241A (fr) 2020-07-22
EA202090735A1 (ru) 2020-06-22
PH12020550029A1 (en) 2021-02-08
CU20200019A7 (es) 2020-11-30
ECSP20022313A (es) 2020-07-31
BR112020003095A2 (pt) 2020-08-25
CN111163756B (zh) 2022-04-15
CO2020002985A2 (es) 2020-05-29
PE20201281A1 (es) 2020-11-24
JP2020533321A (ja) 2020-11-19
CA3070336A1 (en) 2019-03-21
CN111163756A (zh) 2020-05-15
CR20200133A (es) 2020-05-09
US10792271B2 (en) 2020-10-06
JOP20200010A1 (ar) 2022-10-30
US11969403B2 (en) 2024-04-30
EP3681473A1 (en) 2020-07-22
WO2019053657A1 (en) 2019-03-21
US20200390738A1 (en) 2020-12-17
IL273213A (en) 2020-04-30
ZA202000601B (en) 2021-02-24
AU2018332212B2 (en) 2023-03-16
AU2018332212A1 (en) 2020-02-27
US20190083446A1 (en) 2019-03-21
MX2020002898A (es) 2020-11-06
KR20200053476A (ko) 2020-05-18

Similar Documents

Publication Publication Date Title
ECSP17078433A (es) Composiciones de ácido obeticólico y métodos de uso
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
DOP2015000246A (es) Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares
PE20200617A1 (es) Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y metodos de uso de anticuerpos anti-cd39
DOP2018000004A (es) Derivados de oxopiridina sustituidos
CR20160130A (es) Nanopartículas poliméricas terapéuticas y métodos para su elaboración y uso
PE20190563A1 (es) Genes de mini-distrofina optimizados y casetes de expresion y su uso
CO2017002506A2 (es) Nuevos activadores de la guanilato ciclasa soluble y su uso
CL2020000220A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
CL2011002675A1 (es) Uso de compuestos derivados de nitrato o sulfato de 9-purin-9-il-3,4-dihidroxitetrahidrofuran-2-il-metilo para reducir la presion intraocular ; composicion farmaceutica oftalmica que comprende los compuestos; y formulacion oftalmica de uso topico que los comprende.
CO2021005509A2 (es) Derivados de piridinil sulfonamida, composiciones farmacéuticas y usos de estos
UY35455A (es) Inhibidores tripeptidicos de la epoxicetona proteasa
CO2018007535A2 (es) Análogos de cortistatina y usos de los mismos
CL2020000665A1 (es) Formulaciones tópicas de cloroprocaína y métodos para utilizar las mismas.
CO2019011271A2 (es) Análogos de deutetrabenazina, su preparación y uso
CO2019009020A2 (es) Derivados de pirazol como inhibidores de bromodominio.
DOP2015000175A (es) Uso de un péptido natriurético, un péptido diurético o un péptido vasodilatador en la elaboración de un medicamento para tratar una condición cardiovascular
UY37261A (es) Formulación combinada de tres compuestos antivirales
CY1122755T1 (el) Eξισορροπημενες απο αποψη φυσιολογιας ενεσιμες μορφοποιησεις φωσνετουπιταντης
CL2020000221A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
ITUB20160024A1 (it) Nuove composizioni topiche comprendenti acido usnico e loro uso in terapia.
CL2018002010A1 (es) Derivados de indano y su uso en terapias.
BR112018070603A2 (pt) formulações líquidas de fosfaplatina
UY38606A (es) Formulaciones tópicas de cloroprocaína y métodos para utilizar las mismas
CO2017002963A2 (es) Espiro-tiazolonas